Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Equity Average (2016 - 2025)

Historic Equity Average for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $167.4 million.

  • Abeona Therapeutics' Equity Average rose 18131.9% to $167.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.4 million, marking a year-over-year increase of 18131.9%. This contributed to the annual value of $29.4 million for FY2024, which is 4152.74% up from last year.
  • Per Abeona Therapeutics' latest filing, its Equity Average stood at $167.4 million for Q3 2025, which was up 18131.9% from $102.5 million recorded in Q2 2025.
  • Abeona Therapeutics' Equity Average's 5-year high stood at $167.4 million during Q3 2025, with a 5-year trough of $3.0 million in Q1 2024.
  • For the 5-year period, Abeona Therapeutics' Equity Average averaged around $49.3 million, with its median value being $32.2 million (2024).
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 8693.44% in 2024, then surged by 133695.54% in 2025.
  • Over the past 5 years, Abeona Therapeutics' Equity Average (Quarter) stood at $61.1 million in 2021, then plummeted by 67.93% to $19.6 million in 2022, then dropped by 5.87% to $18.4 million in 2023, then soared by 143.61% to $44.9 million in 2024, then skyrocketed by 272.82% to $167.4 million in 2025.
  • Its last three reported values are $167.4 million in Q3 2025, $102.5 million for Q2 2025, and $42.7 million during Q1 2025.